Simultaneous Fat Loss & Lean Tissue Preservation
16-20 weeks
Tirzepatide once weekly + CJC-1295 daily
2 peptides
The body recomposition protocol addresses one of the most challenging goals in metabolic research: reducing fat mass while preserving or increasing lean tissue. Tirzepatide's dual GIP/GLP-1 receptor agonism drives powerful metabolic effects including appetite modulation and improved insulin sensitivity, while CJC-1295's GHRH-mediated GH elevation promotes lipolysis and supports lean tissue maintenance through IGF-1 signaling. This protocol is for research purposes only.
Tirzepatide creates a metabolic environment favorable to fat loss through dual-incretin receptor activation. However, significant caloric deficit typically triggers proteolytic pathways that sacrifice lean tissue. CJC-1295 counteracts this by sustaining elevated GH/IGF-1 levels, which promote fat oxidation while simultaneously activating anti-proteolytic signaling in muscle tissue.
Clinical data shows approximately 25-40% of total weight lost can be lean tissue. This lean mass loss can reduce metabolic rate, impair physical function, and contribute to weight regain. Preserving lean tissue during fat loss is a major research priority.
CJC-1295 sustains elevated GH/IGF-1 levels, which activate anti-proteolytic pathways in muscle tissue and redirect energy metabolism toward fat oxidation, making free fatty acids the preferred fuel source during caloric deficit.
Tirzepatide is administered once weekly. CJC-1295 is administered as a daily subcutaneous injection, typically in the evening. The two peptides operate through distinct receptor systems with no known pharmacological interference.
Gold-standard assessment includes DEXA, which quantifies fat mass, lean mass, and bone mineral density. Research also uses BIA, MRI for visceral fat, and indirect calorimetry for resting metabolic rate.
The metabolic reset protocol focuses on Tirzepatide alone for broad metabolic optimization. The body recomposition protocol adds CJC-1295 specifically to address the lean mass preservation challenge.
Legal under MHRA rules. BPC-157, tirzepatide & NAD+ pens with next-day UK delivery from £99. >99% purity, GMP certified. Shop now.
ARTICLETirzepatide hit 20.9% weight loss vs semaglutide's 14.9% in trials. We compare mechanisms, side effects, and cost. Head-to-head data inside.
ARTICLETirzepatide, semaglutide, and 3 more metabolic peptides compared. Clinical trial data, dosing, side effects, and UK pricing from €169. Expert ranked.
COMPARISONCompare tirzepatide and semaglutide for metabolic research. Dual vs single receptor, efficacy data, side effects, and pricing. Buy tirzepatide pens UK.
COMPARISONCompare ORYN Tirzepatide Pen (10mg daily) vs MediT Pen (40mg weekly). Dosing flexibility, convenience, cost, and which format suits your research. Buy UK.
ENCYCLOPEDIADual GIP/GLP-1 Receptor Agonist (Incretin Mimetic). Molecular weight: 4813.45 Da. Explore mechanism of action, key studies, and research applications.
BUNDLEDual-format tirzepatide for comprehensive metabolic research
PROTOCOLResearch protocol for Tirzepatide peptide pen investigating dual GIP/GLP-1 receptor agonism. Explore metabolic mechanisms, dose titration schedules, and landmark clinical trial data.
FAQTirzepatide research FAQ. Learn about dual GIP/GLP-1 agonist mechanisms, metabolic research, purity, dosing, and ORYN's peptide pen system.
CATEGORYResearch-grade weight loss peptide pens. Tirzepatide dual GIP/GLP-1 agonist for metabolic research. Pre-mixed pens, >99% purity, next-day UK delivery.
CATEGORYResearch-grade peptides for body composition. Tirzepatide, CJC-1295, Ipamorelin, and MediT for fat loss and lean mass. >99% purity, UK delivery.
All ORYN peptide pens are pre-mixed, >99% purity, GMP manufactured with next-day UK delivery.
FOR RESEARCH PURPOSES ONLY. NOT INTENDED FOR SELF-ADMINISTRATION.
SHOP PEPTIDE PENS
